Croda

106 days ago

Video: Skinbiotherapeutics and the scale of the revenue miss, pre placing

A helpful reader supplies a video of a man that certain commentators, habitually resident a long way up a Tyneside rectum, say that I really should respect and not refer to as the bearded, troughing, useless Geordie poltroon. That is to say Skinbiotherapeutics (SBTX) CEO Stuart Ashman. In it he discusses the forecasts published on July 7 by Singer analyst Karl “Kevin” Keegan.

113 days ago

Letter to the FCA and AIM Regulation: Investigation into Stuart Ashman and Skinbiotherapeutics PLC

I just cannot see how Skinbiotherapeutics (SBTX) did not lead investors up the garden path, by omission not act, ahead of the June 16 2025 placing raising £4.2 million at 17p. Heads really should roll and if Nomad Singer is too weak to act against disgraced CEO Stuart Ashman and the company I have written to both the FCA and the Oxymorons at AIM Regulation asking for an immediate enquiry.

113 days ago

Skinbiotherapeutics – poor trading update and schoolboy accounting blunders

Skinbiotherapeutics (SBTX) later than expected trading update has been poorly received by investors: its not only a revenue miss but howling schoolboy errors by the new FD. This is another management clusterfuck and I shall elaborate n that in a bearcast special shortly.

121 days ago

Skinbiotherapeutics: A reader contacts AIM Regulation and the FCA re inaccurate forecasts

I do not disagree with a word in this email. I have also made my views clear to the regulators. It is abundantly clear that forecasts out there are wrong and that the company and ts house broker knows all about it and is happy to see a false market continue. The reader writes:

129 days ago

Croda analysts meeting 2 big takeaways for Skinbiotherapeutics

One will disappoint the conspiracy theorists the other is very good news indeed for Skinbiotherapeutics (SBTX). First for the folks with green biros. Croda stated in the results day analyst briefing:

130 days ago

Skinbiotherapeutics: Letter to the Financial Reporting Council

https://shareprophets.com/81596

136 days ago

Doing Kevin Keegan’s job for him: Forecasting Skins sales prize contest and my forecasts

I am not sure what the prize will be but there will be one. Stuart Ashman has said that the research from analyst “Kevin” Keegan at house broker Singer contain errors and we all know the sales numbers are just plain wrong. I will explain my forecasts for the years ending June 30 2025 and 2026 below. The contest is to give your 2026 forecast and as a tie breaker 2025.

139 days ago

Tom Winnifrith Bearcast: Getting knickers in a twist over that bloody NDA, relax folks!

I am off to see an entrance to the Underworld. Ahead of that a few words on a matter which is making some folks go mad, the Croda (CRDA) NDA with Skinbiotherapeutics (SBTX)

149 days ago

Just when you thought the Cavendish coverage of Skins was utterly crap… Singers makes you look back to a golden past! Its numbers are all wrong!

The Singer’s initiation note on its corporate client Skinbotherapeutics(SBTX) is a curious piece of fish. For staters Singer’s makes it clear that it will not, under any circumstances, be made available to private investors it is for II’s and City HNWIs only. This is pointless.

176 days ago

Naughty Bear Tim Kempster schooled in GCSE science yet again by Stuart Ashman

Oh dear, oh dear, naughty Tim keeps pushing the sort od science that would shame my four year old daughter or perhaps even my cats in support of his undeclared short position in Skinbiotherapeutics (SBTX). He thinks Croda (CRDA)has spaffed £10 million for no reason as, I am sure he knows its business better than Croda does. Luckily Stuart Ashman is here to explain in terms simple enough for even Tim to grasp…

221 days ago

Calling all masochists: reminder Skinbiotherapeutics Investor Meet at 11 AM today

Yes, I still think that shares in Skinbiotherapeutics (SBTX) are cheap at 19p, that there will be three quarters of revenues from Croda booked in the year to June 30 2025 with two quarters fully paid. But I see that the shares are off a penny today because we know what is looming.

225 days ago

Skinbiotherapeutics: Manprick gone and other boardroom changes, more shares bought

Folks like the Lemming thought that Skinbiotherapeutics (SBTX) FD Manprick Randhawa was the bees knees and were jolly cross with me for rebranding him for his patent incompetence. In my view he was useless, unable to communicate with serious investors or to stop Stuart Ashman abusing the word accretive and, at least, partially responsible for the cack handed and dilutive financing of two acquisitions. He was unable to control costs. Well, today, he has gone to pursue other business interests. Great news.. It has prompted me to buy more shares, increasing my holding by 25%.

226 days ago

Tom Winnifrith Bearcast: an apology to an old stockbroker while a young one and I are are baffled, can you assist?

In today's podcast I look at Croda (CRDA) and Skinbiotherapeutics (SBTX), V22, Avacta (AVCT), the biggest threat to your wealth and it is not what Gary Newman et al are foaming at the mouth about, at Cleantech Lithium (CTL) and the disgrace at Anexo (ANX)

226 days ago

Skinbiotherapeutics shares sharply up on Croda 2+2 =27 speculation but who is selling?

Croda (CRDA) has a trading statement out today and the Skinbiotherapeutics (SBTX) obsessives are looking at how revenues from consumer care leapt by £18 million, Quarter on Quarter, to £255 million in Q1 2025. Natch they speculate as to how much of this is Skins related, bearing in mind that Skins would get a double digit margin on whatever is sold. I reckon the answer is “norra lot” but such speculation has pushed the shares up to 25.5p. Now here is my guess for the next RNS!

231 days ago

Tom Winnifrith bearcast: Optibiotix and weight loss pills and Skinbiotherapeutics and the Croda bid rumour

I discuss why the former is not, I believe a threat and why Optibiotix (OPTI) shares are so cheap and on the latter I comment on the idea that Croda (CRDA) might launch a cheeky 50p a share bid for Skinbiotherapeutics (SBTX). FWIW I think its unlikely although stranger things happen at sea.

240 days ago

CEOs do not decide the share price, Mr Market does, more cobblers from Stuart Ashman

I despair at the way that there is nobody with PLC experience to stop Skinbiotherapeutics (SBTX) CEO Stuart Ashman from making a complete tit of himself. Today there is another classic.

256 days ago

Skinbiotherapeutics – just wondering about those interims?

Last year, Skinbiotherapeutics (SBTX) announced on 8 March that its interim results, to December 31, would be out on 22 March and they duly arrived on that day. To be fair to the bearded Geordie poltroon, Stuart Ashman, he has historically been jolly good about issuing an RNS to flag up when results will be out and past performance is, whatever the FCA says, very often a good guide to the future. But…

269 days ago

Skinbiotherapeutics shares up thanks to Elon, Ai & the Lemming

Grok is the AI programme developed by Elon Musk’s twitter and for a bit of sport the Lemming investor invited it to see which of Optibiotix (OPTI), Skinbiotherapeutics (SBTX) and Probiotix (PBX) shares folks should buy. There is a big caveat here. The Lemming notes:

282 days ago

UPDATED: Skinbiotherapeutics, waiting for the TRI which has now arrived, my cynicism unjustified

On 24 February Skinbiotherapeutics (SBTX) announced that David Brierwood had exercised 3.289474 million warrants at c11p. Clueless CEO Stuart Ashman stated:

290 days ago

Tom Winnifrith Bearcast No 2: Skinbiotherapeutics and its NDA and what makes a strong shareholder list

I start with an observation ( supportive) and a question about Tesco (TSCO). then a few thoughts on why interest rate cuts will not necessarily drive growth. Then Skinbiotherapeutics (SBTX) and its Croda NDA. Finally, prompted by PL, what makes a strong shareholder list? 

360 days ago

Cavendish on Skinbiotherapeutics: God save us from Ashman as his M&A hunger is not sated

Skinbiotherapeutics (SBTX) is very simple. If you believe that Croda could deliver £25 million GP or anywhere close to that as CEO Stuart Ashman has intimated the shares are stupendously cheap at 17.75p. Ashman needs to do nothing apart from deliver other corporate deals and more GP from his existing IP and no more shares need be issued. Hell’s teeth why issue shares now or indeed at twice or three times the price given that on Ashman’s Croda numbers the shares could easily be 100p or even 200p! But Ashman is a git.

369 days ago

Has Optibiotix sold Skinbiotherapeutics shares? Steve O’Hara declines to deny

I wonder why shares in SkinBiotherapeutics (SBTX) have not raced ahead more on the news from Croda. One possible explanation put to me by Lemming investor is that Optibiotix (OPTI) has been reducing its holding which was last stated at 10.92%.

925 days ago

SkinBioTherapeutics – SkinBiotix additional formal studies, a short-term delay but enhanced outlook: STRONG BUY

SkinBioTherapeutics (SBTX) has announced on its AxisBiotix-Ps (psoriasis) product that it has commenced sales in Spain aided by the launch of a regional website and on its skin care active ingredient SkinBiotix that partner, cosmetics business of FTSE-100 Croda (CRDA), Sederma has noted ‘exciting’ additional benefits which means delays in monetisation. Is that good news or bad?

1566 days ago

SkinBioTherapeutics – ‘Business Update’, high margin profit potential moving materially closer

SkinBioTherapeutics (SBTX) has delivered a “Business Update” including that the commercial launch of AxisBiotix-Ps is on track for Q4 and has further encouraging potential, that SkinBiotix manufacturing scale-up with Croda (CRDA) is progressing to schedule and 30^th June year-end cash totalled £4.6 million. Sounds good.